Linked Life Data

12806455

Source:http://linkedlifedata.com/resource/pubmed/id/12806455

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12806455rdf:typepubmed:Citationlld:pubmed
pubmed-article:12806455lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:12806455lifeskim:mentionsumls-concept:C0012655lld:lifeskim
pubmed-article:12806455lifeskim:mentionsumls-concept:C1553372lld:lifeskim
pubmed-article:12806455lifeskim:mentionsumls-concept:C0009013lld:lifeskim
pubmed-article:12806455lifeskim:mentionsumls-concept:C0080194lld:lifeskim
pubmed-article:12806455lifeskim:mentionsumls-concept:C0205409lld:lifeskim
pubmed-article:12806455lifeskim:mentionsumls-concept:C0041221lld:lifeskim
pubmed-article:12806455lifeskim:mentionsumls-concept:C0332325lld:lifeskim
pubmed-article:12806455lifeskim:mentionsumls-concept:C0053230lld:lifeskim
pubmed-article:12806455lifeskim:mentionsumls-concept:C0205250lld:lifeskim
pubmed-article:12806455pubmed:issue2lld:pubmed
pubmed-article:12806455pubmed:dateCreated2003-6-13lld:pubmed
pubmed-article:12806455pubmed:abstractTextThe present investigation was performed to evaluate the susceptibility of seven clones isolated from the highly resistant Colombian strains, prototype of Biodeme Type III. Seven clones previously obtained, showed a phenotypic homogeneity and high similarity with the parental strain. Eight groups of 30 mice were inoculated with one of seven clones or the parental strain; 20 were treated with benznidazole (100mg/kg/day) and 10 were untreated controls. Cure evaluations were done by parasitological and serological tests and PCR. Cure rates varied from 0% (null) to 16.7%. Correlation between positivity of parasitological and serological tests with positive PCR reached 37%. The results demonstrated the high resistance of the clones, suggesting the predominance of a highly resistant principal clone in this strain. The findings apparently indicate that the possibility of cure is minimal for patients infected with this biodeme; a fact that could affect the control of Chagas' disease through treatment of chronically infected people.lld:pubmed
pubmed-article:12806455pubmed:languageenglld:pubmed
pubmed-article:12806455pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12806455pubmed:citationSubsetIMlld:pubmed
pubmed-article:12806455pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12806455pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12806455pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12806455pubmed:statusMEDLINElld:pubmed
pubmed-article:12806455pubmed:issn0037-8682lld:pubmed
pubmed-article:12806455pubmed:authorpubmed-author:ReisMitermaye...lld:pubmed
pubmed-article:12806455pubmed:authorpubmed-author:AndradeSonia...lld:pubmed
pubmed-article:12806455pubmed:authorpubmed-author:ReisEliana...lld:pubmed
pubmed-article:12806455pubmed:authorpubmed-author:CamandarobaEd...lld:pubmed
pubmed-article:12806455pubmed:authorpubmed-author:GonçalvesMari...lld:pubmed
pubmed-article:12806455pubmed:issnTypePrintlld:pubmed
pubmed-article:12806455pubmed:volume36lld:pubmed
pubmed-article:12806455pubmed:ownerNLMlld:pubmed
pubmed-article:12806455pubmed:authorsCompleteYlld:pubmed
pubmed-article:12806455pubmed:pagination201-9lld:pubmed
pubmed-article:12806455pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:12806455pubmed:meshHeadingpubmed-meshheading:12806455...lld:pubmed
pubmed-article:12806455pubmed:meshHeadingpubmed-meshheading:12806455...lld:pubmed
pubmed-article:12806455pubmed:meshHeadingpubmed-meshheading:12806455...lld:pubmed
pubmed-article:12806455pubmed:meshHeadingpubmed-meshheading:12806455...lld:pubmed
pubmed-article:12806455pubmed:meshHeadingpubmed-meshheading:12806455...lld:pubmed
pubmed-article:12806455pubmed:meshHeadingpubmed-meshheading:12806455...lld:pubmed
pubmed-article:12806455pubmed:meshHeadingpubmed-meshheading:12806455...lld:pubmed
pubmed-article:12806455pubmed:meshHeadingpubmed-meshheading:12806455...lld:pubmed
pubmed-article:12806455pubmed:meshHeadingpubmed-meshheading:12806455...lld:pubmed
pubmed-article:12806455pubmed:meshHeadingpubmed-meshheading:12806455...lld:pubmed
pubmed-article:12806455pubmed:meshHeadingpubmed-meshheading:12806455...lld:pubmed
pubmed-article:12806455pubmed:meshHeadingpubmed-meshheading:12806455...lld:pubmed
pubmed-article:12806455pubmed:articleTitleTrypanosoma cruzi: susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain.lld:pubmed
pubmed-article:12806455pubmed:affiliationLaboratorio de Doença de Chagas Experimental, Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, BA, Brasil.lld:pubmed
pubmed-article:12806455pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12806455pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12806455lld:pubmed